Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trials.

Tapinarof cream 1% once daily (QD) demonstrated significant efficacy in patients down to age 2 years with atopic dermatitis (AD) in the ADORING 1 and 2 phase 3 trials. We report local tolerability outcomes. Patients received Tapinarof or vehicle cream QD for 8 weeks.

"Age of risk" shapes simpler multimodal communication in the juvenile plains zebra (Equus quagga).

Juveniles occupy a different social niche than adults, engaging in a smaller diversity of social contexts and perceiving greater social risks. Either or both of these factors may influence the form communication takes in immaturity and its developmental trajectory. We investigated the relative influence of these social forces on the development of multimodal communication in plains zebras (Equus quagga).

Plains Zebras Prioritize Foraging Without Sacrificing Social Bonds During a Severe Drought.

Anthropogenically induced climate change has significantly increased the frequency of acute weather events, such as drought. As human activities amplify environmental stresses, animals may be forced to prioritize survival over behaviors less crucial to immediate fitness, such as socializing. Yet, social bonds may also enable individuals to weather the deleterious effects of environmental conditions.

Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children.

Introduction: Tapinarof is a topical aryl hydrocarbon receptor (AhR) agonist in development for the treatment of atopic dermatitis (AD). In two phase 3 trials (ADORING 1 and 2), tapinarof cream 1% once daily (QD) demonstrated significant efficacy and was well tolerated in patients down to age 2 years with AD. Here, we evaluate patient-reported outcomes (PROs), including family impact, with tapinarof in ADORING 1 and 2.

Ecological momentary assessment of cigarette smoking behavior and pain intensity among individuals with chronic back pain who smoke.

Chronic pain affects ~20% of the adult population and is associated with smoking. Smoking and pain worsen each other in the long term, but short-term temporal associations between smoking and pain throughout the day are unclear. Understanding these relationships may inform strategies for managing comorbid smoking and pain.